Real-time enrollment status for this multiple myeloma refractory clinical trial
Current Status
Recruiting
Checked: August 28, 2026 at 12:25 AM UTC
| NCT Number | NCT07096778 |
| Recruiting Status | Recruiting |
| Condition | Multiple Myeloma Refractory |
| Phase | PHASE2 |
| Target Enrollment | 100 participants |
| Active Locations | 20 sites in the US |
| Sponsor | CellCentric Ltd. |
| Last Updated on CT.gov | July 30, 2026 (4 weeks ago) |
As of August 28, 2026: Clinical trial NCT07096778 is currently recruiting participants. This phase2 study for multiple myeloma refractory is actively seeking new participants at 20 locations across the United States. The study is sponsored by CellCentric Ltd.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07096778 is actively recruiting participants as of August 28, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 20 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07096778 was last updated 4 weeks ago (July 30, 2026). HelloStudys verifies this status automatically.